Inotrem Granted Access to Priority Medicines Scheme (PRIME) for Its Lead Compound MOTREM in the Treatment of Septic Shock

November 15, 2017 |

2 min read

The EMA’s PRIME status is granted to promising medicines that may offer a major therapeutic advantage over existing treatments or benefit patients with no treatment options.

Nov. 15, 2017 07:00 UTC

European Medicine Agency’s PRIME status is granted to promising medicines that may offer a major therapeutic advantage over existing treatments or benefit patients with no treatment options.
Accessing PRIME will support the optimization of MOTREM’s^TMdevelopment program.

PARIS--(BUSINESS WIRE)-- Inotrem, a biotechnology company specialized in the control of acute inflammatory syndromes, today announced that the European Medicines Agency (EMA) has granted access to its PRIority MEdicines (PRIME) scheme for its lead product MOTREM^TM in the field of septic shock.

The purpose of PRIME created in 2016 by the EMA is to bring treatments to patients faster by providing early and enhanced support to medicines that have the potential to address patients’ unmet needs. Through the PRIME scheme, Inotrem will be able to optimize the development of its lead compound and accelerate EMA’s regulatory assessment. The inclusion of MOTREM^TM in the PRIME program was supported by the following criteria: (i) there is an important unmet medical need for the treatment of septic shock, (ii) the efficacy of MOTREM^TM could be proven in relevant preclinical models in vivo and (iii) data from a Phase 1 clinical trial showed tolerance in human subjects. Inotrem launched this year a Phase 2 multicenter clinical trial with patients suffering from septic shock in four European countries.

Septic shock is a serious and very debilitating acute condition with high mortality and associated long-term physical, psychological, and cognitive disabilities in survivors. Sepsis, which is characterized by an intense and excessive systemic inflammatory reaction in response to a serious infection, affects worldwide up to 1% of the population annually with a mortality rate of 25 to 40% placing it as the 10th leading cause of death in developed countries and the 1st cause of death in intensive care units. MOTREM^TM is the formulation of the active ingredient LR12, a synthetic peptide capable of controlling the amplification loop of the inflammatory response by inhibiting the TREM-1 receptor, and as such brings the potential of improving hemodynamic parameters and survival rates of septic shock patients. There are currently no specific therapies approved for this indication, and Inotrem’s MOTREM^TM aims at becoming the first mechanism-based personalized medicine for septic shock.

“EMA’s decision to grant our product the PRIME status is an important recognition of both Inotrem’s innovative therapeutic approach in the management of acute inflammation and the critical need for causal therapies in a severe condition such as septic shock. This is also the first time a product being developed in the critical care setting is receiving the PRIME status,” said Jean-Jacques Garaud, M.D., CEO and co-founder of Inotrem. “We are very pleased to be part of this program and look forward to working together with the EMA’s Committee for Medicinal Products for Human Use with their regulatory support to pursue our clinical development plan moving toward the MOTREM^TM marketing authorization process,” added Margarita Salcedo Magguilli, CDO of Inotrem.

www.inotrem.com